PressJanuary 9, 2023 atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depression
PressJanuary 9, 2023 MAPS PBC Announces Positive Results from Confirmatory Phase 3 “MAPP2” Trial of MDMA-Assisted Therapy for Treatment of PTSD
PressJanuary 5, 2023 Tryp Therapeutics Announces Interim Results for Its Phase II Clinical Trial for the Treatment of Binge Eating Disorder With Psilocybin-Assisted Psychotherapy
PressJanuary 5, 2023 PsyBio Announces Closing of First Tranche of Private Placement and Provides Corporate Update
PressJanuary 5, 2023 PsychedelicNewsBreaks – Universal Ibogaine Inc. Recaps 2022, Eyes 2023 as ‘Pivotal Year’
PressJanuary 5, 2023 Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
PressJanuary 5, 2023 Israel-Based Clearmind Medicine Shows Efficacy of Psychedelic- Derived Obesity Treatment in Pre-Clinical Trial
PressJanuary 5, 2023 SciSparc Ltd. Announces Efficacy of Psychedelic-Based Obesity Treatment of Clearmind Medicine Inc. in Pre-Clinical Trial
PressJanuary 5, 2023 Reset Pharmaceuticals Appoints Innes Meldrum as President and Chief Executive Officer
PressJanuary 3, 2023 Tryp Therapeutics and Massachusetts General Hospital Sign Letter of Intent for Clinical Study Investigating the Use of Psilocybin-Assisted Psychotherapy for the Treatment of Patients Suffering From Irritable Bowel Syndrome (IBS)
PressJanuary 3, 2023 Algernon Pharmaceuticals Forms Private Subsidiary to Advance Company’s Psychedelic DMT Stroke Program; Files Form 1-A Offering Statement with U.S. SEC for Regulation A+ Offering
PressDecember 28, 2022 Israel-Based Clearmind Medicine Announces First Clinical Center to Join Its Clinical Trial for Alcohol Use Disorder
PressDecember 28, 2022 Biomind Labs Announces the Completion of the First Sublingual Psychedelic Formulation for Its Drug Candidate BMND08 for Depression and Anxiety in Alzheimer’s Disease
PressDecember 26, 2022 Wellbeing Subsidiary KGK Science Receives Approval for First-of-its-Kind Psylocibin Clinical Trial
PressDecember 26, 2022 Small Pharma Announces Completion of SPL026 Phase IIa Trial and Secures New Intellectual Property
PressDecember 22, 2022 Beckley Psytech Launches Phase IIa Study of Lead Candidate BPL-003, a Novel Benzoate Formulation of 5-MeO-DMT, for Treatment Resistant Depression
